Nathan Beaver and Marika Miller Quoted on DEA Proposal on Special Registration for Telemedicine
Foley & Lardner LLP attorneys Nathan Beaver and Marika Miller are quoted in the healthleaders article, “Prescribing Pullback: Telehealth Advocates Ask Trump to Withdraw DEA Proposal.”
Writing in a Foley Health Care Law Today blog cited in the article, Beaver and Miller write in their analysis of the U.S. Drug Enforcement Administration proposed rule for Special Registation for telemedicine that given “widespread frustration” with the DEA’s previous iterations of this proposed rule, it is unlikely that the final version will resemble its current form.
One roadblock in particular the authors highlight is the requirement that practitioners with a Special Registration check a patient’s controlled substance prescription data in Prescription Drug Monitoring Programs (PDMPs) of certain jurisdictions before issuing a prescription for controlled substances via telemedicine.
They add that this requirement “is seen as overly burdensome given the absence of a nationwide PDMP database—a burden the DEA continues to underestimate.”
Their commentary also appeared in PSQH.